Locally Advanced Clear Cell Renal Cell CarcinomaPhase 2NEBULANCT07840001
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
A Phase 2 study testing Belzutifan and Pembrolizumab in people with Locally Advanced Clear Cell Renal Cell Carcinoma, run by Peter MacCallum Cancer Centre, Australia at 1 site in Australia.
Trial summary
The purpose of this study is to compare the safety and effectiveness of two new treatments: belzutifan alone or belzutifan in combination with pembrolizumab before kidney surgery and followed by a combination of belzutifan and pembrolizumab treatment post-surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Locally Advanced Clear Cell Renal Cell Carcinoma
- What is being tested?
- Belzutifan and Pembrolizumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteAustralia
- Study dates
- Dec 2026to Apr 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient has provided written informed consent using the NEBULA Main PICF.
- Adults aged 18 years or older at the time of written informed consent.
- Histologically or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer (8th edition), with or without sarcomatoid features.
- Patients who in the opinion of the treating surgeon require nephrectomy.
- Patient has high risk ccRCC as defined by the following pathological tumour-node metastasis and tumour grading: • cT2b, Nany, Gany • cT3-cT4, N0, Gany • cTany, cN1, Gany
- Patient has evaluable primary tumour disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST1.1).
Show all 13Show fewer
- Patients has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 10 days prior to randomisation.
- Patient has a Karnofsky performance score of at least 70% within 10 days prior to randomisation.
- Patients must have adequate bone marrow, hepatic and renal function documented within 10 days prior to randomisation, defined as: • Haemoglobin (Hgb) ≥ 100 g/L. Criteria must be met without erythropoietin dependency and without peripheral red blood cell transfusion within 4 weeks before the haematology screening assessment. • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. • Platelets ≥ 100 x 109/L. • Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 30 mL/min calculated using the Cockcroft-Gault equation (Appendix 1) or 24-hour urine collection. • Total bilirubin ≤ 1.5 x ULN ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 × ULN. • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 × ULN for patients with liver metastases). • International normalisation ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy as long as INR/PT or aPTT is within therapeutic range of intended use of anticoagulants.
- Women of childbearing potential (WCBP) must agree to use a highly effective contraceptive method (with a failure rate of < 1%) as outlined in Section 9.10.1 during study treatment and for 30 days after the last dose of belzutifan or 120 days after the last dose of pembrolizumab, whichever occurs last and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same time period.
- A WCBP must have a negative highly sensitive urine or serum pregnancy (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to randomisation.
- Male patients are eligible to participate if they agree to the following during the treatment period and for at least 7 days after the last dose of belzutifan: • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WCBP who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration. • Male patients must also agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person of any sex.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing surgery, treatment, scheduled visits, and examinations.
Who cannot join
- Presence of extensive tumour thrombus that necessitates early surgical intervention as per primary treating urologist.
- cT1 or cT2a Gany.
- Metastatic disease, or resected M1 disease.
- Has received prior systemic therapy for ccRCC.
- Has received prior radiotherapy for ccRCC.
- Has any of the following: • Pulse oximeter reading < 92% at rest. • Requires intermittent supplemental oxygen. • Requires chronic supplemental oxygen.
Show all 24Show fewer
- Has clinically significant cardiovascular disease within 6 months prior to randomisation, including NYHA III or IV congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident, undergone coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, or cardiac arrhythmia. Note: Medically controlled arrhythmia stable on medication is permitted.
- Has other clinically significant disorders such as: • Serious active nonhealing wound/ulcer/bone fracture. • Requirement for haemodialysis or peritoneal dialysis.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy exceeding 10 mg daily dose of prednisone or equivalent or any other form of immunosuppressive therapy within 7 days prior to randomisation.
- Has an active autoimmune disease that has required systemic treatment in the last 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
- Has a known additional malignancy that is progressing or has required active treatment in the last 3 years. Note: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ, such as breast cancer in situ, that has undergone potentially curative therapy are not excluded.
- Has known active central nervous system metastases and/or carcinomatous meningitis.
- Has received colony-stimulating factors (e.g., G-CSF, GM-CSF) or recombinant erythropoietin or transfusion within 28 days prior to randomisation. 14. Is unable to swallow orally administered medication or has a history or current evidence of a gastrointestinal condition (e.g., inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver function or diseases that in the opinion of the investigator may significantly alter the absorption or metabolism of oral study intervention.
- Has a severe hypersensitivity (Grade ≥ 3) reaction to belzutifan or pembrolizumab and/or any of their excipients.
- Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- Has an active infection, requiring systemic therapy.
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C (defined as Hepatitis C virus [HCV] RNA [qualitative] is detected) infection.
- Has received a live virus vaccine or live-attenuated vaccine within 30 days prior to randomisation. Note: Administration of killed vaccines is allowed.
- Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate, in the opinion of the treating investigator.
- Has a known psychiatric or substance abuse disorder that would interfere with the patient's ability to cooperate with the requirements of the study.
- Has had a prior solid organ transplant.
- Is breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through to 30 days after the last dose of belzutifan or 120 days after the last dose of pembrolizumab, whichever occurs last.
- Any contraindications for surgery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Australia1 site
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000
PCCTU MoncA, +61 3 8559 5000, PCCTU.MoncA@petermac.org
About this study
The purpose of this study is to compare the safety and effectiveness of two new treatments: belzutifan alone or belzutifan in combination with pembrolizumab before kidney surgery and followed by a combination of belzutifan and pembrolizumab treatment post-surgery.
Belzutifan is a small molecule drug that specifically blocks a protein called Hypoxia-Inducible Factor 2 alpha (HIF-2α) and slows down or stops the growth of cancer. Belzutifan has been shown to provide better treatment results in kidney cancer compared to other drugs that target similar proteins to stop cancer growth.
Read more
Pembrolizumab is a type of medicine called an immunotherapy drug. It helps the immune system spot and attack kidney cancer cells by blocking a "stop sign" that the cancer uses to hide and help slow down or shrink the cancer.
The combined use of molecules similar to belzutifan and pembrolizumab has shown promising results in treating kidney cancer, although effectiveness depends on the specific combination. This treatment combination is experimental and is not approved to treat kidney cancer in Australia. This means that it must be tested to see if it is an effective treatment combination for kidney cancer prior to kidney surgery.
Read the detailed description
This is a prospective, open label, single site, phase II, randomised, clinical trial, evaluating neoadjuvant belzutifan with or without pembrolizumab prior to nephrectomy, follow by adjuvant belzutifan plus pembrolizumab.
Patients identified as potential candidates for the NEBULA study will be asked to sign a Pre-Screening Patient Information and Consent Form (PICF) before undergoing a biopsy. The biopsy will be used to establish a diagnosis of ccRCC as per standard of care and for the collection of pre-treatment tissue samples for translational research for this trial. Patients with a confirmed diagnosis of ccRCC and found to fulfill the remaining eligibility criteria will be invited to participate in the NEBULA study. Patients without a confirmed diagnosis of ccRCC will be deemed ineligible.
Approximately 30 eligible patients will be randomised for neoadjuvant treatment to receive one of the following: Arm A: Belzutifan alone for 2 cycles. Arm B: Belzutifan and pembrolizumab for 2 cycles. All patients will undergo nephrectomy after completion of Cycle 2 neoadjuvant treatment. Both a nephron sparing (partial) or total nephrectomy is an acceptable standard of care and choice of approach is at the surgeon's discretion. After nephrectomy, patients will receive adjuvant treatment with belzutifan and pembrolizumab for up to 9 cycles in Arm A and 7 cycles in Arm B.
At the time of treatment discontinuation for any reason, visits will be conducted. Patients with non-progressive disease will then enter the follow-up phase of the trial. Patients with progressive disease or start a new anti-ccRCC therapy at any time will complete a progression visit and will subsequently be followed only for survival and start of new anti-ccRCC therapy. All patients will be followed for 2 years after the last patient has been randomised.
- Being tested
- Belzutifan, Pembrolizumab
- Keywords
- Clear Cell Renal Cell Carcinoma, ccRCC, NEBULA, Belzutifan, Pembrolizumab, Locally Advanced Clear Cell Renal Cell Carcinoma
- Medical subject headings
- Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BelzutifanDrug
Belzutifan orally at 120mg per day
PembrolizumabDrug
IV pembrolizumab 400 mg on Day 1 of each cycle
| Study group | Role | What they receive |
|---|---|---|
| Belzutifan alone | Experimental | Belzutifan alone for 2 cycles during neoadjuvant treatment. Post nephrectomy, all patients will receive adjuvant treatment with belzutifan and pembrolizumab. Receives: Drug: Belzutifan |
| Belzutifan plus pembrolizumab | Experimental | Belzutifan and pembrolizumab for 2 cycles during neoadjuvant treatment. Post nephrectomy, all patients will receive adjuvant treatment with belzutifan and pembrolizumab. Receives: Drug: Belzutifan; Drug: Pembrolizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Therapeutic effects of belzutifan with and without pembrolizumab on the proportion of viable tumour cells in the neoadjuvant setting
The proportion of viable tumour cells per patient post-neoadjuvant therapy as assessed by pathology
Measured: Up to 18 weeks. From randomisation to the completion of nephrectomy
Secondary outcomes (3)
EFS rates between belzutifan with and without pembrolizumab neoadjuvant treatment plus adjuvant treatment arms.
Event-free survival after belzutifan with and without pembrolizumab in the neoadjuvant setting and adjuvant pembrolizumab plus belzutifan.
Measured: Up to 20 months. From randomisation to the first date of documented radiographic progression using conventional imaging, discontinuation of trial treatment, or death due to any cause, whichever occurs first.
Pathological response rates between belzutifan with and without pembrolizumab neoadjuvant treatment
Pathological response rates between belzutifan with and without pembrolizumab neoadjuvant treatment
Measured: Up to 18 weeks. From randomisation to the completion of nephrectomy
Safety of belzutifan with and without pembrolizumab in the neoadjuvant and adjuvant settings.
Occurrence of AEs graded according to Common Terminology Criteria for Adverse Events, Version 5 (CTCAE v5.0) after belzutifan with and without pembrolizumab in the neoadjuvant and adjuvant settings.
Measured: Up to 21 months. From randomisation until 30 days after the last dose of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study startDec 2026 (estimated)
- Primary completionApr 2029 (estimated)
- Study completionApr 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Locally Advanced Clear Cell Renal Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, open label, single site, phase II, randomised, clinical trial.
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peter MacCallum Cancer Centre, Australia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lewis Au, PhD, MBBS, Principal investigator, Peter MacCallum Cancer Centre, Australia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07840001
- Sponsor's protocol ID
- 25/232
- Acronym
- NEBULA
- Status last verified
- Sep 2026
- First submitted
- 14 Sep 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
- ClinicalTrials.gov ID
- NCT07840001
- Acronym / sponsor ID
- NEBULA / 25/232
- Keywords
- Clear Cell Renal Cell Carcinoma, ccRCC, NEBULA, Belzutifan, Pembrolizumab, Locally Advanced Clear Cell Renal Cell Carcinoma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Peter MacCallum Cancer Centre, AustraliaUniversity, hospital or other
- Study start
- Dec 2026 (estimated)
- Primary completion
- Apr 2029 (estimated)
- Study completion
- Apr 2030 (estimated)
- First posted
- 24 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the safety and effectiveness of two new treatments: belzutifan alone or belzutifan in combination with pembrolizumab before kidney surgery and followed by a combination of belzutifan and pembrolizumab treatment post-surgery.
Belzutifan is a small molecule drug that specifically blocks a protein called Hypoxia-Inducible Factor 2 alpha (HIF-2α) and slows down or stops the growth of cancer. Belzutifan has been shown to provide better treatment results in kidney cancer compared to other drugs that target similar proteins to stop cancer growth.
Pembrolizumab is a type of medicine called an immunotherapy drug. It helps the immune system spot and attack kidney cancer cells by blocking a "stop sign" that the cancer uses to hide and help slow down or shrink the cancer.
The combined use of molecules similar to belzutifan and pembrolizumab has shown promising results in treating kidney cancer, although effectiveness depends on the specific combination. This treatment combination is experimental and is not approved to treat kidney cancer in Australia. This means that it must be tested to see if it is an effective treatment combination for kidney cancer prior to kidney surgery.
Detailed description
This is a prospective, open label, single site, phase II, randomised, clinical trial, evaluating neoadjuvant belzutifan with or without pembrolizumab prior to nephrectomy, follow by adjuvant belzutifan plus pembrolizumab.
Patients identified as potential candidates for the NEBULA study will be asked to sign a Pre-Screening Patient Information and Consent Form (PICF) before undergoing a biopsy. The biopsy will be used to establish a diagnosis of ccRCC as per standard of care and for the collection of pre-treatment tissue samples for translational research for this trial. Patients with a confirmed diagnosis of ccRCC and found to fulfill the remaining eligibility criteria will be invited to participate in the NEBULA study. Patients without a confirmed diagnosis of ccRCC will be deemed ineligible.
Approximately 30 eligible patients will be randomised for neoadjuvant treatment to receive one of the following: Arm A: Belzutifan alone for 2 cycles. Arm B: Belzutifan and pembrolizumab for 2 cycles. All patients will undergo nephrectomy after completion of Cycle 2 neoadjuvant treatment. Both a nephron sparing (partial) or total nephrectomy is an acceptable standard of care and choice of approach is at the surgeon's discretion. After nephrectomy, patients will receive adjuvant treatment with belzutifan and pembrolizumab for up to 9 cycles in Arm A and 7 cycles in Arm B.
At the time of treatment discontinuation for any reason, visits will be conducted. Patients with non-progressive disease will then enter the follow-up phase of the trial. Patients with progressive disease or start a new anti-ccRCC therapy at any time will complete a progression visit and will subsequently be followed only for survival and start of new anti-ccRCC therapy. All patients will be followed for 2 years after the last patient has been randomised.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prospective, open label, single site, phase II, randomised, clinical trial.
| Arm | Type | Receives |
|---|---|---|
| Belzutifan alone | Experimental | Drug: BelzutifanBelzutifan alone for 2 cycles during neoadjuvant treatment. Post nephrectomy, all patients will receive adjuvant treatment with belzutifan and pembrolizumab. |
| Belzutifan plus pembrolizumab | Experimental | Drug: Belzutifan, Drug: PembrolizumabBelzutifan and pembrolizumab for 2 cycles during neoadjuvant treatment. Post nephrectomy, all patients will receive adjuvant treatment with belzutifan and pembrolizumab. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Patient has provided written informed consent using the NEBULA Main PICF.
- Adults aged 18 years or older at the time of written informed consent.
- Histologically or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer (8th edition), with or without sarcomatoid features.
- Patients who in the opinion of the treating surgeon require nephrectomy.
- Patient has high risk ccRCC as defined by the following pathological tumour-node metastasis and tumour grading: • cT2b, Nany, Gany • cT3-cT4, N0, Gany • cTany, cN1, Gany
Key exclusion criteria (24 listed)
- Presence of extensive tumour thrombus that necessitates early surgical intervention as per primary treating urologist.
- cT1 or cT2a Gany.
- Metastatic disease, or resected M1 disease.
- Has received prior systemic therapy for ccRCC.
- Has received prior radiotherapy for ccRCC.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BelzutifanBelzutifan orally at 120mg per day | Drug | Belzutifan alone, Belzutifan plus pembrolizumab |
| PembrolizumabIV pembrolizumab 400 mg on Day 1 of each cycle | Drug | Belzutifan plus pembrolizumab |
Primary outcome
Therapeutic effects of belzutifan with and without pembrolizumab on the proportion of viable tumour cells in the neoadjuvant setting
Time frame: Up to 18 weeks. From randomisation to the completion of nephrectomy
The proportion of viable tumour cells per patient post-neoadjuvant therapy as assessed by pathology
3 secondary outcomes
EFS rates between belzutifan with and without pembrolizumab neoadjuvant treatment plus adjuvant treatment arms.
Time frame: Up to 20 months. From randomisation to the first date of documented radiographic progression using conventional imaging, discontinuation of trial treatment, or death due to any cause, whichever occurs first.
Pathological response rates between belzutifan with and without pembrolizumab neoadjuvant treatment
Time frame: Up to 18 weeks. From randomisation to the completion of nephrectomy
Safety of belzutifan with and without pembrolizumab in the neoadjuvant and adjuvant settings.
Time frame: Up to 21 months. From randomisation until 30 days after the last dose of treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Locally Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Active, not recruitingPhase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors, NSCLC
Active, not recruitingPhase 2
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lewis Au, PhD, MBBS principal investigator
Peter MacCallum Cancer Centre, Australia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Belzutifan and Pembrolizumab in people with Locally Advanced Clear Cell Renal Cell Carcinoma, run by Peter MacCallum Cancer Centre, Australia at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ruth Columbus, PhD (+61 3 8559 7364, CRDO@petermac.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Therapeutic effects of belzutifan with and without pembrolizumab on the proportion of viable tumour cells in the neoadjuvant setting (time frame: Up to 18 weeks. From randomisation to the completion of nephrectomy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.